Bariatric surgery

Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s

Retrieved on: 
木曜日, 5月 30, 2024
Managed Care, Software, Other Health, General Health, Mobile, Wireless, Telemedicine, Virtual Medicine, Apps, Applications, Technology, Medical Devices, Artificial Intelligence, Fitness & Nutrition, Surgery, Health, Digital health, Patient, Obesity, Bariatric surgery, Internal medicine, Artificial intelligence, VCS, Gastroenterology, AI, Attention, Communication, Weight loss, Entrepreneurship, Medical device

They can also engage with Coach Iris for tailored meal plans, recipes, exercise routines, stress management techniques, and motivational insights.

Key Points: 
  • They can also engage with Coach Iris for tailored meal plans, recipes, exercise routines, stress management techniques, and motivational insights.
  • Coach Iris is part of the VCS, a dynamic weight-loss management suite powered by AI and featuring remote patient monitoring, predictive analytics, telehealth, and care team collaboration.
  • The VCS is available to healthcare professionals offering GLP-1 and other anti-obesity medication therapy, bariatric surgery, and weight loss devices.
  • We immediately saw the immense value of Coach Iris and how it will help our patients stay engaged throughout their weight loss journey,” said Paul Barros, Co-Founder and CEO of Pivot Weight Loss .

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

Retrieved on: 
水曜日, 5月 15, 2024
Insurance, Security (finance), NYU Langone Health, Prescription, Marketing, Patent, Obesity, Travel, PTE, FLEX, Bariatrics, Division, NYU, Advertising, Annual report, Bariatric surgery, Weight loss, Research, United States patent law, C-peptide, Pharmaceutical industry

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update.

Key Points: 
  • The patent, number 11974934, was issued on May 7, 2024 and provides protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
  • January 2024: Conducted bariatric fellows training for their Lap-Band® System, highlighting the Lap-Band® 2.0 FLEX.
  • Gross Profit for both three months ended March 31, 2023 and 2024, was $1.2 million.
  • Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.

Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss

Retrieved on: 
水曜日, 5月 15, 2024
Health Technology, Fitness & Nutrition, Health, Surgery, Patient, E pluribus unum, ECO, Composition, Interest, Bariatric surgery, Gaur, European, Uptake, Center of mass, Facial muscles, Congress, Caloric deficit, Sustainability, Body composition, Behavior, Weight loss, Skeletal muscle, Dietary supplement

Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion’s proprietary behavior change program.

Key Points: 
  • Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion’s proprietary behavior change program.
  • “The Allurion Program was designed to monitor both weight loss and lean body mass, facilitate basic changes in behavior that can protect skeletal muscle, and reduce the impact on lean body mass during periods of rapid weight loss,” said Dr. Shantanu Gaur, Founder and CEO of Allurion.
  • For example, GLP-1s have been shown to lead to approximately 40% lean body mass loss at one year of treatment.1,2
    “Maintaining lean body mass in the setting of significant caloric deficit is a challenge.
  • We believe the Allurion Program makes this possible with its body composition monitoring and a personalized program that focuses on outcomes beyond just weight,” said Dr. Ram Chuttani, Chief Medical Officer of Allurion.

Dameron Hospital Selects DoseMeRx to Advance Precision Dosing

Retrieved on: 
月曜日, 5月 13, 2024
Software, Pharmaceutical, General Health, Health, Data Management, Hospitals, Health Technology, Technology, Partnership, Patient, Pharmacist, Bariatric surgery, Adventist Health, Safety, AUC, Elective surgery, Adventism, Cardiology, Kidney, Pharmaceutical industry

DoseMe , a leading provider of model-informed precision dosing (MIPD), is proud to announce its partnership with Dameron Hospital, Managed by Adventist , to deploy its sophisticated dosing platform.

Key Points: 
  • DoseMe , a leading provider of model-informed precision dosing (MIPD), is proud to announce its partnership with Dameron Hospital, Managed by Adventist , to deploy its sophisticated dosing platform.
  • Dameron Hospital’s adoption of DoseMeRx stands as a testament to our collective drive for excellence and innovation in patient care.
  • DoseMeRx’ Bayesian dosing platform creates great efficiencies while delivering better care, and we are thrilled to provide ongoing support for the Dameron Hospital initiative.”
    The application of precision dosing is particularly crucial for patients with renal impairment, where the individualization of drug dosing is critical to ensure safety and effectiveness.
  • For a comprehensive overview into the capabilities of DoseMeRx and its role in advancing precision dosing, please visit https://doseme-rx.com/why-dosemerx/drug-packages

Studies Find Erectile Dysfunction Commercial Bias Is More Prevalent On TikTok Than YouTube

Retrieved on: 
土曜日, 5月 4, 2024
Urology, Social media, Bias, American Urological Association, Abstract (summary), Abstract, Cleveland Clinic, MD, Research, Erectile dysfunction, Patient, Annual general meeting, SAN, Bariatric surgery

SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss how urologists need to continue to remain relevant on social media to counteract misinformation and commercial bias on erectile dysfunction.

Key Points: 
  • SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss how urologists need to continue to remain relevant on social media to counteract misinformation and commercial bias on erectile dysfunction.
  • Researchers will present their study findings covering important updates on sexual function in San Antonio, TX, from May 3 to 6.
  • Petar Bajic, MD, urologist and director of men’s health at the Cleveland Clinic, moderated a virtual press session with the abstract authors, providing key insights into their research.
  • “We also are going to see how bariatric surgery for obese patients may have an impact on their sex lives.”
    The following abstracts are covered in the moderated panel:

Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey

Retrieved on: 
木曜日, 5月 2, 2024
Diabetes, General Health, Fitness & Nutrition, Health, Doctor of Philosophy, Congress, Virtual, AI, Bariatric surgery, Fidelity, Weight loss, Metabolism, Patient, Society, DSM-IV codes, Karger Publishers, Evolution, Behavior, Gastric balloon

In addition, 72% of patients reported that three years after the Program, their eating habits had remained healthier.

Key Points: 
  • In addition, 72% of patients reported that three years after the Program, their eating habits had remained healthier.
  • "Long-term weight maintenance after significant weight loss is notoriously difficult to achieve,” said Dr. Shantanu Gaur, Founder and CEO of Allurion.
  • “The Allurion Program is intended to deliver a significant amount of weight loss in a short period of time and simultaneously help individuals make durable changes to their lifestyle and behavior.
  • Ienca R et al., The Evolution of the Allurion Program for Long-Term Weight Loss: From Virtual Monitoring to a Virtual Care Suite.

LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

Retrieved on: 
火曜日, 4月 30, 2024
Cardiology, Biotechnology, Surgery, Health, FDA, Mental Health, Medical Devices, Clinical Trials, University, Boğaziçi University, Allergan, Inc., LivaNova, Innovation, Research, LIVN, Patient, Chemical engineering, PLC, Bariatric surgery, Tezel

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024.
  • “I am very pleased to welcome Ahmet to the LivaNova team.
  • At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advancing this vision.
  • As Chief Innovation Officer, Ahmet will advance LivaNova’s ability to create novel solutions and elevate the quality of care in neurological and cardiac health for patients around the world,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova.

AMRA Medical’s Innovative Fat Z-Score Biomarkers Show Tirzepatide Treatment is Associated with a Potential Targeted Effect on Visceral Fat and Liver Fat

Retrieved on: 
水曜日, 4月 10, 2024
Biotechnology, Other Health, Diabetes, Health, General Health, Pharmaceutical, Health Technology, Other Science, Research, Surgery, Science, Disorder, T2D, Connective tissue, Bariatric surgery, Eli Lilly, Human, Weight, Tirzepatide, Metabolism, Obesity, Type 2 diabetes, Patient, Society, Magnetic resonance imaging, MRI, Multimedia, ASMBS, Medical imaging

For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.

Key Points: 
  • For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.
  • The personalized fat z-scores were introduced through research published in 2023 linking fat distribution patterns, as described by the z-scores, to specific cardiometabolic disease risk profiles in the general population.
  • The results showed that treatment with tirzepatide was associated with a significant reduction in visceral fat z-score (-0.18 SD) and liver fat z-score (-0.54 SD), while the subcutaneous fat z-score increased from an initially negative value (+0.11 SD) - suggesting a therapeutically-induced shift towards a better-balanced body fat distribution with prominent visceral and liver fat loss.
  • The significant reduction of visceral fat and liver fat z-scores observed with tirzepatide in SURPASS-3 MRI indicates a potential targeted effect beyond that expected by the magnitude of weight reduction.

Rising Trends in Medical Tourism: Reports Show Millions of Americans Flock to Mexico For Bariatric Surgery And Plastic Surgery

Retrieved on: 
水曜日, 4月 24, 2024
Patient, Interview, Safety, Infection, Travel, Simon Fraser University, The New York Times, Medical tourism, Anesthesia, NPR, SAN, Bariatric surgery, Health insurance

SAN DIEGO, April 24, 2024 /PRNewswire-PRWeb/ -- According to a report published in the New York Post, approximately 1.2 million residents of the United States travel to Mexico each year for elective surgeries, seeking significant cost savings. These surgeries, including procedures such as plastic surgery and weight loss surgery in Mexico, can offer savings of up to 80% compared to similar procedures in the US.

Key Points: 
  • From body transformations to cosmetic enhancements, procedures like bariatric and plastic surgery in Mexico offer jaw-dropping savings of up to 80% compared to US prices.
  • These surgeries, including procedures such as plastic surgery and weight loss surgery in Mexico , can offer savings of up to 80% compared to similar procedures in the US.
  • Driven by increasing demand for weight loss surgery and cosmetic surgery, Mexico is witnessing the establishment of state-of-the-art hospitals and medical centers.
  • Notably, a 33-story medical facility in Tijuana, near San Diego, has positioned itself as a top-tier medical tourism destination.

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
月曜日, 4月 1, 2024
Commitment, Research, Obesity, PTE, Exercise, Bariatrics, Patent, Patient, Food and Drug Administration, Weight loss, Travel, Acquisition, FLEX, Prescription, NYU, Food, Security (finance), Insurance, Marketing, Surgeon, C-peptide, Annual report, PMA, NYU Langone Health, Division, United States patent law, FDA, Advertising, Bariatric surgery

IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate strategic update.

Key Points: 
  • Specifically, it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819.
  • December 2023: Engaged Maxim Group LLC, to act as the company’s exclusive financial advisor to help identify potential synergistic merger and acquisition partnerships.
  • December 2023: Received U.S. Food and Drug Administration (FDA) PMA supplement approval for its next-generation Lap-Band® 2.0 FLEX, designed to improve the patient experience.
  • Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.